About Satralizumab
            
            Class: | Monoclonal antibody (anti-IL-6 receptor)  
Use: | Treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults and pediatric patients aged 12 years and older who are anti-aquaporin-4 antibody positive  
Adult dose: | Initial dose: 120 mg subcutaneously at weeks 0, 2, and 4; Maintenance dose: 120 mg subcutaneously every 4 weeks thereafter  
Pediatric dose: | Safety and efficacy not established in patients under 12 years; for patients aged 12 years and older, the same dosing as a
         
        
            
                
                
                    
                        Drug Class
                    
                    Monoclonal antibody (anti-IL-6 receptor)
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults and pediatric patients aged 12 years and older who are anti-aquaporin-4 antibody positive
                 
                
                
                    
                        Storage Requirements
                    
                    Store in the refrigerator at 2°C to 8°C (36°F to 46°F); do not freeze; may be stored at room temperature (up to 25°C or 77°F) for a maximum of 7 days
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: F. Hoffmann-La Roche Ltd., SWITZERLAND
                    
                    
                    Package Size
                    1ml Prefilled Syringe x 1
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 46006.39
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        Initial dose: 120 mg subcutaneously at weeks 0, 2, and 4; Maintenance dose: 120 mg subcutaneously every 4 weeks thereafter
                    
                    
                        Pediatric Dose
                    
                    
                        Safety and efficacy not established in patients under 12 years; for patients aged 12 years and older, the same dosing as adults applies
                    
                 
                
                
                    
                        Side Effects
                    
                    Headache, injection site reactions, upper respiratory tract infections, nausea, and fatigue
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Hypersensitivity to satralizumab or any component of the formulation; active infections
         
        
        
            
                Important Warnings
            
            Risk of serious infections; monitor for signs of infection; may cause hypersensitivity reactions; not recommended for use in patients with active or untreated infections
         
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.